Generic Name: somatrogon
Brand Name: TBC
Manufacturer: Pfizer Canada ULC
Therapeutic Area: Growth hormone deficiency
Indications: Long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone.
Manufacturer Requested Reimbursement Criteria1: Long-term treatment of pediatric patients who have growth hormone deficiency.
Submission Type: Initial
Project Status: Pending
Call for patient/clinician input open: April 5, 2021
Call for patient/clinician input closed: May 28, 2021
Anticipated Date: June 3, 2021
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.